SPTX — Seaport Therapeutics, Inc.
Is SPTX overbought or oversold? Here is the current MarketMoodz read.
Seaport Therapeutics, Inc. (SPTX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $19.12. The rating moved from Overbought to Oversold on November 13, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$19.12
- Last changeMoved from Overbought to Oversold on November 13, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Seaport Therapeutics, Inc. exhibits a typical early-stage biotech risk/reward profile: upside tied to clinical or partnership catalysts and downside dominated by funding needs, clinical binary risk and low liquidity. Absent recent filings or public sentiment signals, near-term price action is likely to track sector sentiment and macro risk appetite. Positive trial readouts or strategic collaborations could materially lift value, while negative data or capital markets pressure would likely compress the share price. Monitor cash runway, upcoming milestone/calendar events, and any partnering announcements as the principal drivers of near-term performance.
Key factors
- Early-stage biotech profile with limited public financial disclosure increases dependency on clinical and partnership milestones for valuation re-rating
- Sector-wide acquisitive appetite from large-cap pharma and active licensing deals could create M&A or collaboration avenues for niche assets
- Defensive market flows and lack of sector conviction in the near term reduce probability of broad speculative rallies for small-cap biotech names
- Clinical pipeline potential (platform/lead asset optionality) can generate binary upside if positive data or regulatory progress is announced
- Capital runway and funding cadence likely to be a primary determinant of share performance absent near-term clinical readouts
- No recent EDGAR or social sentiment data available, resulting in limited market signal clarity
Risks
- Clinical trial failure or disappointing data could cause sharp downside in valuation
- Insufficient cash runway or need to raise dilutive capital under adverse market conditions
- Regulatory setbacks or slower-than-expected approvals for therapeutics
- Low liquidity and wide bid-ask spreads that can amplify volatility and hinder exits
- Commercialization risk if late-stage progress is achieved but partnering/commercial strategy is unclear
- Macro risk from risk-off market moves and sector rotation away from small biotech
See today's live rating, score and targets
Members see the live hourly rating for SPTX — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.